GRDN vs MDLN vs CAH Stock Comparison

Guardian Pharmacy Services, Medline and Cardinal Health Prices as of Nov 13, 2026 Peers: Industry group
MDLN Medline Inc.
$39.47 +9.9% 1M
Market cap
$34.37B
P/E
40.9x
Revenue (TTM)
$30.68B
Div. yield
–
Medical Supplies Healthcare
CAH Cardinal Health Inc
$281.08 +13.4% 1M +36.4% 1Y
Market cap
$65.90B
P/E
36.2x
Revenue (TTM)
$257.75B
Div. yield
0.01%
Drug Distribution Healthcare
7 wins

Head to Head

10 decided of 12

Cardinal Health leads on 7 of the 12 questions below (Cardinal Health 7, Guardian Pharmacy Services 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGRDNMDLNCAHLeader
Larger companyMarket capitalisation $3.12B $34.37B $65.90B CAH
Cheaper on earningsLower P/E, profitable companies only 41.7x 40.9x 36.2x CAH
Cheaper on forward earningsLower price / next fiscal year consensus EPS 37.5x 26.5x 22.8x CAH
Faster revenue growthRevenue growth, trailing twelve months +4.9% — +10.0% CAH
More profitableNet margin, trailing twelve months 5.1% 2.7% 0.7% GRDN
Better return on capitalReturn on invested capital — 4.3% 36.5% CAH
Less leveragedLower net debt / EBITDA — 3.2x 1.0x CAH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.01% –
Better 1-year returnPrice return, last 12 months +62.6% — +36.4% GRDN
Better 5-year returnAnnualised price return, 5 years — — +40.5%/yr –
Less volatileAnnualised volatility, 1 year 42.4% 47.8% 25.9% CAH
Higher overall scoreMean of the five percentile scores vs peers 71/100 53/100 60/100 GRDN

Percentile Scorecard

GRDNMDLNCAH

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGRDNMDLNCAH
Valuation 23 #21 of 27 78 #54 of 243 77 #7 of 27
Growth 76 #7 of 26 – 68 #9 of 26
Profitability 96 #2 of 26 73 #60 of 222 60 #11 of 26
Financial Health 88 #4 of 26 43 #143 of 248 40 #16 of 26
Shareholder Returns – 17 #132 of 158 53 #9 of 18
Overall 71 53 60
  • GRDN ranked among 27 companies in Healthcare Payers and Distributors
  • MDLN ranked among 252 companies in Medical Devices and Diagnostics
  • CAH ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGRDNMDLNCAHSPY
1 month +21.9%+9.9%+13.4% -2.0%
3 months +28.7%+10.4%+19.5% -2.8%
6 months +35.1%+9.1%+44.0% +2.0%
Year to date +64.4%-6.0%+36.8% +10.6%
1 year +62.6%—+36.4% +12.2%
3 years ——+173.2% +68.1%
3 years, per year ——+39.8% +18.9%
5 years ——+446.4% +61.4%
5 years, per year ——+40.5% +10.1%
10 years ——+293.8% +248.5%
10 years, per year ——+14.7% +13.3%

Risk

MeasureGRDNMDLNCAHSPY
Volatility, 1Y 42.4%47.8%25.9% 13.6%
Downside volatility, 1Y 39.1%48.2%24.8% 13.9%
Beta vs S&P 500, 1Y 0.710.74-0.01 1.00
Return / volatility, 1Y 1.48—1.41 0.90
Max drawdown, 5Y -27.2%-36.7%-21.0% -25.4%
From 52-week high -1.1%-21.0%0.0% -3.2%
52-week high $50.01$49.99$281.08 $779.14
52-week low $27.03$31.64$182.50 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGRDNMDLNCAH
P/E now vs peer median 41.9xmedian 25.2x 41.1xmedian 26.5x 35.9xmedian 25.2x
P/S now vs peer median 2.2xmedian 0.4x 1.7xmedian 2.7x 0.3xmedian 0.4x
EV/EBITDA now vs peer median 25.6xmedian 14.5x 21.6xmedian 18.4x 18.7xmedian 14.5x
P/FCF now vs peer median 40.0xmedian 16.5x 27.4xmedian 25.4x 13.3xmedian 16.5x
P/B now vs peer median 11.2xmedian 2.7x 2.7xmedian 2.5x -21.5xmedian 2.7x
PEG now vs peer median —median 1.72 —median 0.98 0.40median 1.72

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGRDNMDLNCAH
Revenue $1.46B $30.68B $257.75B
Gross profit $327.08M $7.90B $10.05B
Operating income $94.14M $1.74B $2.70B
Net income $74.77M $889.00M $1.82B
Free cash flow $78.35M $1.90B $4.90B
EPS (diluted) $1.17 $0.64 $7.80
Cash & equivalents $119.66M $2.32B $5.26B
Total debt – $12.58B $8.82B
Shares (diluted) 63.92M 1.32B 233.00M
Enterprise value $2.78B $23.91B $49.06B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGRDNMDLNCAH
P/E 41.9x 41.1x 35.9x
P/FCF 40.0x 27.4x 13.3x
P/Operating cash flow 27.5x 21.8x 11.6x
P/S 2.2x 1.7x 0.3x
P/B 11.2x 2.7x -21.5x
P/Tangible book 12.1x 8.6x -21.5x
EV/EBITDA 25.6x 21.6x 18.7x
EV/EBIT 32.0x 35.0x 25.4x
EV/Revenue 2.1x 2.0x 0.3x
EV/FCF 38.5x 32.1x 14.0x
EV/Operating cash flow 26.4x 25.6x 12.2x
PEG (3Y EPS CAGR) – – 0.40

Growth

14 metrics
MetricGRDNMDLNCAH
Revenue growth (1Y) 4.9% – 10.0%
Revenue CAGR (3Y) – – 7.1%
Gross profit growth (1Y) 19.2% – 17.1%
Gross profit CAGR (3Y) – – 12.6%
Operating income growth (1Y) 60.4% – 13.6%
Operating income CAGR (3Y) – – 63.6%
Net income growth (1Y) 85.8% – 13.6%
Net income CAGR (3Y) – – 86.5%
EPS growth (1Y) 84.4% – 16.9%
EPS CAGR (3Y) – – 90.8%
Operating cash flow growth (1Y) 29.6% – 11.6%
Operating cash flow CAGR (3Y) – – 18.7%
Free cash flow growth (1Y) 18.9% – 10.1%
Free cash flow CAGR (3Y) – – 19.9%

Profitability

14 metrics
MetricGRDNMDLNCAH
Gross margin 22.4% 25.7% 3.9%
EBITDA margin 8.1% 9.2% 1.4%
Operating margin 6.5% 5.7% 1.0%
Pretax margin 7.2% 3.6% 0.9%
Net margin 5.1% 2.7% 0.7%
FCF margin 5.4% 6.2% 1.9%
Operating cash flow margin 7.8% 7.8% 2.2%
Return on equity 28.3% 4.6% –
Return on assets 16.3% 2.2% 3.1%
Return on invested capital – 4.3% 36.5%
Return on capital employed 32.6% 4.8% 22.3%
Asset turnover 3.1x 0.8x 4.4x
Cash conversion (OCF / net income) 1.5x 2.7x 3.1x
Stock comp / revenue 0.6% 0.4% 0.1%

Financial Health

11 metrics
MetricGRDNMDLNCAH
Debt / assets – 31.3% 14.8%
Debt / equity – 0.6x -2.9x
Net debt / EBITDA – 3.2x 1.0x
Debt / FCF – 6.6x 1.8x
Liabilities / assets 43.1% 51.7% 105.1%
Equity / assets 56.9% 48.3% -5.1%
Interest coverage 145.3x – 7.9x
Current ratio 1.6x 4.0x 0.9x
Quick ratio 1.3x 2.4x 0.4x
Cash ratio 0.7x 1.2x 0.1x
Altman Z-score 13.09 2.70 5.05

Shareholder Returns

7 metrics
MetricGRDNMDLNCAH
Dividend yield – – 0.7%
Net buyback yield – -13.6% 2.3%
Shareholder yield – -13.6% 3.0%
Payout ratio (earnings) – – 26.8%
Payout ratio (FCF) – – 10.0%
Dividend growth (1Y) – – -1.4%
Dividend CAGR (3Y) – – -1.7%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGRDNMDLNCAH
Forward P/E 37.5xFY2026 26.5xFY2026 22.8xFY2027
EPS, next fiscal year $1.32FY2026 $1.49FY2026 $12.31FY2027
EPS growth, next FY +23.4%FY2026 +4.2%FY2026 +9.3%FY2027
EPS growth, the year after +18.9% +9.4% +12.8%
Revenue, next fiscal year $1.42BFY2026 $32.69BFY2026 $273.40BFY2027
Revenue growth, next FY -2.2%FY2026 +15.0%FY2026 +7.5%FY2027
Revenue growth, the year after +2.7% +8.2% -3.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGRDNMDLNCAH
Held by institutions 58.6% 57.1% 87.4%
Institutions holding 189 409 1,494
Change in shares held, QoQ +3.8% +17.9% +2.8%
Institutions buying 109 322 711
Institutions selling 54 69 559
Buyers to sellers 2.02 4.67 1.27

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GRDNMDLNCAH
GRDN 1.00 0.12 0.15
MDLN 0.12 1.00 0.28
CAH 0.15 0.28 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GRDN, MDLN and CAH?

Cardinal Health (CAH) is the largest by market capitalisation: Guardian Pharmacy Services (GRDN) $3.12B, Medline (MDLN) $34.37B, Cardinal Health (CAH) $65.90B.

Which stock is cheaper, GRDN, MDLN and CAH?

Cardinal Health (CAH) trades on the lowest price-to-earnings ratio (Guardian Pharmacy Services (GRDN) 41.7x, Medline (MDLN) 40.9x, Cardinal Health (CAH) 36.2x). On next year's consensus earnings, Cardinal Health (CAH) is cheapest (Guardian Pharmacy Services (GRDN) 37.5x, Medline (MDLN) 26.5x, Cardinal Health (CAH) 22.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Cardinal Health (CAH) grew revenue fastest over the trailing twelve months: Guardian Pharmacy Services (GRDN) +4.9%, Cardinal Health (CAH) +10.0%.

Which company is more profitable?

Guardian Pharmacy Services (GRDN) has the highest net margin (Guardian Pharmacy Services (GRDN) 5.1%, Medline (MDLN) 2.7%, Cardinal Health (CAH) 0.7%). On return on invested capital, Cardinal Health (CAH) leads (Medline (MDLN) 4.3%, Cardinal Health (CAH) 36.5%).

Which stock has performed better?

Over the past year Guardian Pharmacy Services (GRDN) returned the most: Guardian Pharmacy Services (GRDN) +62.6%, Cardinal Health (CAH) +36.4%. Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Guardian Pharmacy Services (GRDN) 0.00%, Medline (MDLN) 0.00%, Cardinal Health (CAH) 0.01%. Guardian Pharmacy Services (GRDN) and Medline (MDLN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Cardinal Health (CAH) has been the steadiest (Guardian Pharmacy Services (GRDN) 42.4%, Medline (MDLN) 47.8%, Cardinal Health (CAH) 25.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GRDN, MDLN and CAH?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Cardinal Health (CAH) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.